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Table 2. Studies comparing urine steroid profiling results in patients with adrenocortical carcinoma (ACC) and patients with 
adrenocortical adenoma (ACA) 
 
Author
, year 
Period of 
data 
collection 
Type of 
study 
Sample 
size 
(n) 
Women 
(n, %) 
Age of 
diagnosis 
(years) 
Tumor size 
(cm) 
ACC ACA 
n Hormone excess n Hormone excess 
Arlt, 
2011 1 
 
 
2003-
2006 
Retro-
spective 
6 centers 
147 84 
(57%) 
ACA (median, 
ranges): 60 (19-
84) 
 
ACC (median, 
ranges): 55 (20-
80) 
ACA (median, 
ranges): 2.6 (0.9-
7.8) 
 
ACC (median, 
ranges): 9 (1.4-23) 
45 None – 12 (27%) 
Cortisol – 11 (24%) 
Androgen – 7 
(16%) 
Cortisol + androgen 
– 12 (27%) (2 also 
with aldosterone) 
Estrogen – 3 (7%) 
(in combination 
with cortisol in 2 
and androgen in 1 
patient) 
102 None – 69 (68%) 
Cortisol – 14 (14%) 
Aldosterone – 13 
(13%) 
Cortisol + 
aldosterone – 4 (4%) 
Androgen – 2 (2%) 
Kerkhof
s, 2015 
2 
2000-
2011 
Retro-
spective 
2 centers 
152 
(include
s 18 
non-
cortical 
tumors) 
100 
(66%) 
All adrenal 
tumors (mean, 
SD): 56(13) 
All adrenal tumors 
(median, ranges): 
3.5 (0.8-17) 
27 None – 7 (26%) 
Hormone excess in 
20 (74%) –single or 
in combination 
including: 
Cortisol – 18 (67%) 
Androgen in 14 
(52%) 
Estrogen in 1 (4%) 
107 None – 85 (79%) 
Cortisol – 19 (18%) 
Aldosterone – 3 (3%) 
 
Velikan
ova, 
2016 3 
2014-
2015 
Retro-
spective 
3 centers 
139 83 
(60%) 
Non-functioning 
ACA (median, 
ranges):  
55 (50-61) 
Cortisol-
secreting ACA 
(median, 
ranges): 48 (21-
54) 
ACC (median, 
ranges): 43 (33-
57) 
Non-functioning 
ACA (median, 
ranges):   
3.3 (2.3-4.5) 
Cortisol-secreting 
ACA (median, 
ranges)::  
3 (2.5-4.2) 
ACC (median, 
ranges): 9.1 (7.2-
11) 
31 Hormone excess 
reported for cortisol 
only in 13 (42%) 
patients; other 
hormonal excess 
was not reported 
 
108 None – 52 (48%) 
Cortisol - 44 (41%) 
Aldosterone - 12 
(11%) 
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